Open Access

Synthesis and antimicrobial evaluation of new 1,4-dihydro-4-pyrazolylpyridines and 4-pyrazolylpyridines

  • Om Prakash1,
  • Khalid Hussain2,
  • Ravi Kumar3Email author,
  • Deepak Wadhwa4,
  • Chetan Sharma5 and
  • Kamal R Aneja5
Organic and Medicinal Chemistry Letters20111:5

DOI: 10.1186/2191-2858-1-5

Received: 21 March 2011

Accepted: 3 August 2011

Published: 3 August 2011

Abstract

Background

Dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates (1,4-DHP) have now been recognized as vital drugs. Some of these derivatives such as amlodipine, felodipine, isradipine, etc. have been commercialized. In view of wide range of biological properties associated with 1,4-DHP and owing to the biological importance of the oxidation step of 1,4-DHP, we carried out the synthesis and antimicrobial evaluation of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g).

Results

Synthesis of a series of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) has been accomplished by multicomponent cyclocondensation reaction of ethyl acetoacetate, 3-aryl-1-phenyl pyrazole-4-carboxaldehyde (1a-g) and ammonium acetate. The dihydropyridines 2a-g were smoothly converted to new diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g) using HTIB ([Hydroxy (tosyloxy)iodo]benzene, Koser's reagent) as the oxidizing agent. The antimicrobial studies of the title compounds, 2a-g & 3a-g, are also described.

https://static-content.springer.com/image/art%3A10.1186%2F2191-2858-1-5/MediaObjects/13588_2011_Article_4_Figa_HTML.gif

Keywords

1,4-Dihydro-4-pyrazolylpyridines 4-pyrazolylpyridines HTIB oxidation antibacterial activity antifungal activity

Background

Dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates (1,4-DHP; Figure 1) have now been recognized as vital drugs. Some of these derivatives, such as amlodipine, felodipine, isradipine, etc. have been commercialized, and it has been proven that their therapeutic success is related to their efficacy to bind to calcium channels and consequently to decrease the passage of the transmembrane calcium current [13]. Further, cerebrocrast, a dihydropyridine derivative, has been introduced as a neuroprotective agent [4]. Together with calcium channel blocker and neuroprotective activity, a number of dihydropyridine derivatives have been found as vasodilators, antihypertensive, bronchodilators, antiatherosclerotic, hepatoprotective, antitumour, antimutagenic, geroprotective, antidiabetic and antiplatelet aggregation agents [59]. In a recent article, 4-[5-chloro-3-methyl-1-phenyl-1H-pyrazol-4-yl]-dihydropyridines have been shown to possess significant antimicrobial activity [10].
https://static-content.springer.com/image/art%3A10.1186%2F2191-2858-1-5/MediaObjects/13588_2011_Article_4_Fig1_HTML.jpg
Figure 1

1,4-DHP.

In addition to above, aromatization of 1,4-DHP has also attracted considerable attention in recent years as Böcker has demonstrated that metabolism of the above drugs involves a cytochrome P-450 catalysed oxidation in the liver [11].

In view of wide range of biological properties associated with 1,4-DHP and the biological importance of the oxidation step of 1,4-DHP, we carried out the synthesis and antimicrobial evaluation of new diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g).

Results and discussion

Chemistry

The synthetic scheme used for the synthesis of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g) is outlined in Scheme 1. Synthesis of the title compounds 2a-g was accomplished by multicomponent cyclocondensation reaction of ethyl acetoacetate, 3-aryl-1-phenyl-pyrazole-carboxaldehyde (1a-g) and ammonium acetate in ethanol. The purity of the compounds was checked by TLC and elemental analysis. Spectral data (IR, 1H NMR (see additional files 1, 2, 3, 4 and 5, mass) of the newly synthesized compounds 2a-g were in full agreement with their proposed structures. The IR spectra of compounds 2a-g exhibited characteristic peak at approximately 1697 cm-1 because of the presence of ester group (-COOEt), and peak due to -N-H stretch appeared in the region 3300-3317 cm-1. In 1H NMR of compounds 2a-g, the protons of C4-H and -NH of the dihydropyridine ring resonate between δ 5 and 6 ppm.
https://static-content.springer.com/image/art%3A10.1186%2F2191-2858-1-5/MediaObjects/13588_2011_Article_4_Sch1_HTML.gif
Scheme 1

Synthesis of 1,4-DHP (2) and aromatization of 2 to 3 using HTIB.

Hypervalent iodine (III) and iodine (V) reagents have been used as green-oxidants for a variety of substrates [1217]. Amongst the various reagents used, HTIB has been reported to serve as a mild, fast and efficient oxidant for the aromatization of Hantzsch 1,4-dihydropyridines to pyridines [18].

Thus, diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g) were further oxidized by treating with HTIB (Koser's reagent) in dichloromethane (CH2Cl2) at room temperature to afford new diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (3a-g) in good-to-excellent yields (Scheme 1). All the compounds 3a-g were unambiguously characterized on the basis of their spectral (IR, 1H NMR (see additional files 6, 7, 8, 9, 10, 11 and 12) and mass) and elemental data.

A plausible mechanism for the oxidation of dihydropyridines 2 to 3 is outlined in Scheme 2. The probable mechanism might involve the attack by N-H on PhI(OH)OTs, leading to the formation of intermediate 4. The intermediate 4 finally loses a molecule of iodobenzene (PhI) to give 3.
https://static-content.springer.com/image/art%3A10.1186%2F2191-2858-1-5/MediaObjects/13588_2011_Article_4_Sch2_HTML.gif
Scheme 2

Proposed mechanism for the oxidation of 2 to 3.

Pharmacology

All the synthesized compounds, 2a-g and 3a-g, were evaluated in vitro for their antibacterial activity against two gram-positive bacterial strains, Staphylococcus aureus & Bacillus subtilis and two gram-negative bacteria, namely, Escherichia coli and Pseudomonas aeruginosa and their activities were compared with a well-known commercial antibiotic, ciprofloxacin. In addition, the synthesized compounds were also evaluated for their antifungal activity against Aspergillus niger & Aspergillus flavus and their antifungal potential was compared to reference drug, fluconazole. Compounds possessed variable antibacterial activities against Gram-positive bacteria, S. aureus, B. subtilis. However, the compounds in this series were not effective against any Gram-negative bacteria, neither against E. coli nor against P. aeruginosa. Results of antibacterial evaluation are summarized in Table 1.
Table 1

Antibacterial activity of chemical compounds through agar well diffusion method

Compound

Diameter of growth of inhibition zone (mm)a

 

S. aureus

Bacillus Subtilis

E. coli

P. aeruginosa

2a

15.6

16.3

-

-

2b

18.6

15.6

-

-

2c

16.3

15.6

-

-

2d

17.6

16.3

-

-

2e

16

15.3

-

-

2f

15.6

14

-

-

2g

15.3

16.6

-

-

3a

20

19.3

-

-

3b

15

15.6

-

-

3c

15.3

16.6

-

-

3d

16.6

14.6

-

-

3e

16.6

18.3

-

-

3f

15.3

16.6

-

-

3g

16.3

18.6

-

-

Ciprofloxacin

27.6

26.3

25.0

25.3

-, No activity

aValues, including diameter of the well (8 mm), are means of three replicates

Compounds 2a-g and 3a-g showed zones of inhibition ranging between 14 and 20 mm. On the basis of the zones of inhibition produced against the test bacteria, compounds 2b and 3a were found to be most effective against S. aureus, showing the maximum zones of inhibition at 18 and 20 mm, respectively, and compounds 3a, 3e and 3g were found to be most effective against B. subtilis. The remaining compounds showed fair activity against gram-positive bacterial strains (Table 1). In the whole series, the MIC (minimum inhibitoty concentration) values of various tested chemical compounds ranged between 64 and 256 μg/mL against gram-positive bacteria. Compounds 2b and 3a displayed good antibacterial activity with the lowest MIC value, 64 μg/ml against S. aureus. Three compounds, 3a, 3e and 3g possessed antibacterial activity with MIC value of 64 μg/mL against B. subtilis (Table 2).
Table 2

MIC (in μg/mL) of compounds obtained using macrodilution method

Compound

S. aureus

Bacillus Subtilis

Compound

S. aureus

Bacillus

Subtilis

2a

128

128

3a

64

64

2b

64

128

3b

128

128

2c

128

128

3c

128

128

2d

128

128

3d

128

256

2e

128

128

3e

128

64

2f

128

256

3f

128

128

2g

128

128

3g

128

64

Ciprofloxacin

5

5

   
Amongst the synthesized compounds, six compounds 2a, 2d, 2g, 3a, 3c and 3d showed more than 50% mycelial growth inhibition against A. niger whereas compounds, 2a, 2e, 2f, 3a, 3d and 3f were found to be active against A. flavus (Table 3).
Table 3

Antifungal activity of chemical compounds through poisoned food method (mycelial growth inhibition) (%)

Compound

A. niger

A. flavus

Compound

A. niger

A. flavus

2a

51.1

58.8

3a

52.5

51.1

2b

50

44.4

3b

48.8

45.5

2c

48.8

50

3c

51.1

50

2d

52.5

48.8

3d

55.5

52.5

2e

45.5

51.1

3e

45.5

44.4

2f

47.7

52.5

3f

50

51.1

2g

51.1

48.8

3g

48.8

44.4

Fluconazole

81.1

77.7

   

From the overall result it is evident that compound 3a could be identified as the most biologically active member within this study with good antifungal and antibacterial profile.

Conclusions

A series of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (2a-g) and diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g) has been synthesized with the hope of discovering new structure leads. Compounds 2b and 3a were found to be most effective against S. aureus showing the maximum zones of inhibition of 18 and 20 mm, respectively, and compounds 3a, 3e and 3g were found to be most effective against B. subtilis. Moreover, six compounds 2a, 2d, 2g, 3a, 3c and 3d showed more than 50% mycelial growth inhibition against A. niger whereas compounds, 2a, 2e, 2f, 3a, 3d and 3f were found to be active against A. flavus; however, no compound was found superior over the reference drug.

Finally, compound 3a could be identified as the most biologically active member within this study with an interesting antibacterial and antifungal profile.

Experimental

Chemical synthesis

Melting points were taken in open capillaries and are uncorrected. IR spectra were recorded on Perkin-Elmer IR spectrophotometer. The 1H NMR spectra were recorded on Brucker 300 MHz instrument. The chemical shifts are expressed in ppm units downfield from an internal TMS standard. 3-Aryl-1-phenylpyrazole-4-carboxaldehydes (1a-h), needed for the present study, were synthesized by Vilsmeier-Haack reaction according to the literature procedure [19].

Synthesis of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)

General procedure: A mixture of appropriate 3-aryl-1-phenylpyrazole-4-carboxaldehyde (1, 10 mmol), ethyl acetoacetate (20 mmol) and ammonium acetate (22 mmol) in ethanol was allowed to reflux on water bath for 25-30 min. After completion of the reaction, the reaction mixture was cooled to room temperature to give pure diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g).

Characterization data of diethyl 1,4-dihydro-2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl) pyridine-3,5-dicarboxylates (2a-g)

2a: M.p.: 124°C; yield: 74%; IR (νmax, cm-1, KBr): 3323 (NH stretch), 1690 (-COOEt), 1207; 1H NMR (CDCl3, δ, ppm): 1.069-1.115 (t, 6H), 2.237 (s, 6H), 3.744-4.068 (m, 4 H), 5.318 (s, 1 H), 5.544 (s, 1 H), 7.221-7.424 (m, 4 H), 7.806 (s, 1 H), 7.681-7.868 (m, 6 H); mass: m/z 472.30 (M+ + 1, 100%).

Anal. Calcd for C28H29N3O4: C 71.33, H 6.15, N 8.91; found: C 71.34, H 6.18, N 8.94; C 71.33, H 6.15, N 8.91.

2b: M.p.: 189°C; yield: 70%; IR (νmax, cm-1, KBr): 3325 (NH stretch), 1697 (-OOEt), 1643, 1211; 1HNMR (CDCl3, δ, ppm): 1.032-1.087 (t, 6 H), 2.225 (s, 6 H), 2.401 (s, 3 H), 3.730-4.095 (m, 4 H), 5.306 (s, 1 H), 5.722 (bs, 1 H), 7.205-7.282 (m, 3 H), 7.381-7.450 (m, 2 H), 7.664-7.692 (m, 2 H), 7.733 (s, 1 H), 7.742-7.769 (d, 2 H, J = 8.1 Hz); mass: m/z 486.20 (M+ + 1, 100%).

Anal. Calcd for C29H31N3O4: C 71.75, H 6.39, N 8.66; found: C 71.71, H 6.42, N 8.66.

2c: M.p.: 139°C; yield: 78%; IR (νmax, cm-1, KBr): 3317 (NH stretch), 1697 (-COOEt), 1643, 1211; 1H NMR (CDCl3, δ, ppm): 1.079-1.127 (t, 6 H), 2.250 (s, 6 H), 3.866 (s, 3 H), 3.801-4.102 (m, 4 H), 5.288 (s, 1 H), 5.561 (s, 1 H), 6.962-6.991 (d, 2 H, J = 8.7 Hz), 7.209-7.440 (m, 3 H), 7.670-7.697 (d, 2 H, J = 8.7 Hz) 7.742 (s, 1 H), 7.785-7.814 (d, 2 H, J = 8.7 Hz); mass: m/z 502.32 (M+ + 1, 100%).

Anal. Calcd for C29H31N3O5: C 69.46, H 6.19, N 8.38; found: C 69.42, H 6.24, N 8.37.

2d: M.p.: 175°C; yield: 72%; IR (νmax, cm-1, KBr): 3333 (NH stretch), 1697 (-COOEt), 1643, 1211; 1H NMR (CDCl3, δ, ppm): 0.940-0.975 (t, 6 H), 2.521 (s, 6 H), 4.102-4.132 (m, 4 H), 5.175 (s, 1 H), 5.562 (s, 1 H), 6.962-6.991 (d, 2 H, J = 8.7 Hz), 7.281-7.513 (m, 5 H), 7.734 (d, 2 H, J = 7.5 Hz), 7.922 (s, 1 H); mass: m/z 490.26 (M+ + 1, 100%)

Anal. Calcd for C28H28N3O4F: C 68.71, H 5.73, N 8.58; found: C 68.72, H 5.75, N 8.56.

2e: M.p.: 185°C; Yield: 76%; IR (νmax, cm-1, KBr): 3317 (NH stretch), 1697 (-COOEt), 1636, 1211; 1H NMR (CDCl3, δ, ppm): 1.072-1.119 (t, 6 H), 2.280 (s, 6 H), 3.790-4.080 (m, 4 H), 5.285 (s, 1 H), 5.551 (s, 1 H), 7.235-7.454 (m, 5 H), 7.668-7.694 (d, 2 H) 7.814 (s, 1 H), 7.863-7.891 (d, 2 H, J = 8.4 Hz); mass: m/z 506.26, 508.24.

Anal. Calcd for C28H28N3O4Cl: C 66.47, H 5.54, N 8.31; found: C 66.47, H 5.55, N 8.31.

2f: M.p.: 174°C; yield: 72%; IR (νmax, cm-1, KBr): 3564 (NH stretch), 1728 (-COOEt), 1242; 1H NMR (CDCl3, δ, ppm): 1.072-1.119 (t, 6 H), 2.275 (s, 6 H), 3.764-4.104 (m, 4 H), 5.284 (s, 1 H), 5.581 (s, 1 H), 7.234-7.452 (m, 3 H), 7.561-7.588 (d, 2 H, J = 7.8 Hz), 7.665-7.691 (d, 2 H, J = 7.8 Hz) 7.753 (s, 1 H), 7.806-7.834 (d, 2 H, J = 8.4 Hz); mass: m/z 550.31, 552.31.

Anal. Calcd for C28H28N3O4Br: C 61.20, H 5.10, N 7.65; found: C 61.09, H 5.14, N 7.64.

2g: M.p.: 198°C; yield: 70%; IR (νmax, cm-1, KBr): 3302 (NH stretch), 1697 (-COOEt), 1636, 1211; 1H NMR (CDCl3, δ, ppm): 1.026-1.071 (t, 6 H), 2.325 (s, 6 H), 3.775-4.047 (m, 4 H), 5.335 (s, 1 H), 5.766 (s, 1 H), 7.282-7.473 (m, 4 H), 7.684-7.709 (d, 2 H, J = 7.5 Hz), 7.801 (s, 1 H), 8.254-8.344 (m, 3 H); mass: m/z 517.29 (M+ + 1, 100%).

Anal. Calcd for C28H28N4O6: C 65.11, H 5.42, N 10.85; found: C 65.13, H 5.47, N 10.83.

Synthesis of diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g)

General procedure: To a solution of appropriate 1,4-DHP (2, 10 mmol) in dichloromethane, was added HTIB (12 mmol) and the mixture was stirred at room temperature. The progress of the reaction was monitored by TLC. Reaction was completed in 4-5 min. After the completion of reaction, the reaction mixture was washed with aqueous NaHCO3 solution. Organic phase was then separated, dried and concentrated on water bath. Crude product, thus obtained, was purified by silica gel column chromatography using Pet ether/EtOAc (20:1) as eluent to afford pure diethyl 2,6-dimethyl-4-(3-aryl-1-phenyl-4-pyrazolyl)pyridine-3,5-dicarboxylates (3a-g).

Characterization data of dimethyl 2,6-dimethyl-4-pyrazolylpyridine-3,5-dicarb oxylates (3a-g)

3a: M.p.: 111°C; yield: 68%; IR (νmax, cm-1, KBr): 1736, 1233; 1H NMR (CDCl3, δ, ppm): 0.911-0.997 (t, 6 H), 2.613 (s, 6 H), 3.910-4.07 (m, 4 H), 7.110-7.313 (m, 4 H), 7.817 (s, 1 H), 7.581-7.690 (m, 6 H); mass: m/z 470.20 (M+ + 1, 100%).

Anal. Calcd for C28H27N3O4: C 71.64, H 5.76, N 8.95; found: C 71.63, H 5.79, N 8.93.

3b: M.p.: 105°C; yield: 69%; IR (νmax, cm-1, KBr): 1720, 1234; 1H NMR (CDCl3, δ, ppm): 0.913-0.960 (t, 6 H), 2.611 (s, 6 H), 2.468 (s, 3H), 3.923-4.072 (q, 4 H), 6.839-6.868 (d, 2H, J=8.7 Hz), 7.280-7.501 (m, 5 H), 7.732-7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z 484.40 (M+ + 1, 100%).

Anal. Calcd for C29H29N3O4: C 72.05, H 6.00, N 8.70; found: C 72.06, H 6.05, N 8.70.

3c: M.p.: 136°C; Yield- 72%; IR (νmax, cm-1, KBr): 1740, 1034; 1H NMR (CDCl3, δ, ppm): 0.913-0.998 (t, 6 H), 2.612 (s, 6 H), 3.808 (s, 3 H), 3.924-4.08 (q, 4 H), 6.835-6.864 (d, 2 H, J = 8.7 Hz), 7.311-7.501 (m, 5 H), 7.732-7.759 (d, 2 H, J = 8.7 Hz), 7.905 (s, 1 H); mass: m/z 500.29 (M+ + 1, 100%).

Anal. Calcd for C29H29N3O5: C 69.73, H 5.81, N 8.41; found: C 69.71, H 5.83, N 8.40.

3d: M.p.: 121°C; yield: 70%; IR (νmax, cm-1, KBr): 1728, 1236, 1037; 1H NMR (CDCl3, δ, ppm): 0.924-0.971 (t, 6 H), 2.615 (s, 6 H), 3.905-4.105 (q, 4 H), 6.987-7.044 (m, 2 H), 7.280-7.365 (m, 1 H), 7.469-7.622 (m, 4 H), 7.733-7.759 (d, 2 H, J = 7.8 Hz), 7.923 (s, 1 H); mass: m/z 488.36 (M+ + 1, 100%).

Anal. Calcd for C28H26N3O4F: C 68.99, H 5.38, N 8.62; found: C 68.95, H 5.37, N 8.63.

3e: M.p.: 101-102°C, lit [20] M.p.: 101-102°C; Yield: 65%.

3f: M.p.: 115°C; yield: 70%; IR (νmax, cm-1, KBr): 1734, 1030; 1H NMR (CDCl3, δ, ppm): 0.940-0.962 (t, 6 H), 2.617 (s, 6 H), 3.957-4.039 (q, 4 H), 7.200-7.495 (m, 7 H), 7.732-7.756 (d, 2 H, J = 7.2 Hz), 7.921 (s, 1 H); mass: m/z 548.20, 550.20.

Anal. Calcd for C28H26N3O4Br: C 61.42, H 4.75, N 7.68; found: C 61.31, H 4.79, N 7.69.

3g: M.p.: 172°C; yield: 68%; IR (νmax, cm-1, KBr): 1728, 1234, 1034; 1H NMR (CDCl3, δ, ppm): 0.895-0.941 (t, 6 H), 2.632 (s, 6 H), 3.923-4.039 (m, 4 H), 7.279-7.410 (m, 3 H), 7.499-7.769 (m, 4 H), 7.960 (s, 1 H), 8.178-8.207 (d, 2 H, J = 7.5 Hz); mass: m/z 515.26 (M+ + 1, 100%).

Anal. Calcd for C28H26N4O6: C 64.37, H 4.98, N 10.73; found: C 65.34, H 5.08, N 10.87.

Pharmacology

Test microorganisms

Total six microbial strains were selected on the basis of their clinical importance in causing diseases in humans. Two Gram-positive bacteria (S. aureus MTCC 96 and B. subtilis MTCC 121); two Gram-negative bacteria (E. coli MTCC 1652 and P. aeruginosa MTCC 741) and two fungi (A. niger and A. flavus) the ear pathogens isolated from the patients of Kurukshetra [21], were used in the present study for the evaluation of antimicrobial activities of the chemical compounds. All the cultures were procured from Microbial Type Culture Collection (MTCC), IMTECH, Chandigarh. The bacteria and fungi were subcultured on Nutrient agar and Sabouraud's dextrose agar (SDA), respectively, and incubated aerobically at 37°C.

In vitro antibacterial activity

The antibacterial activities of compounds, 2a-g and 3a-g, were evaluated by the agar well diffusion method. All the cultures were adjusted to 0.5 McFarland standard, which is visually comparable to a microbial suspension of approximately 1.5 × 108 cfu/mL. 20 mL of Mueller Hinton agar medium was poured into each Petri plate, and the agar plates were swabbed with 100 μL inocula of each test bacterium and kept for 15 min for adsorption. Using sterile cork borer of 8-mm diameter, wells were bored into the seeded agar plates, and these were then loaded with a 100 μL volume with concentration of 2.0 mg/mL of each compound reconstituted in the dimethylsulphoxide (DMSO). All the plates were incubated at 37°C for 24 h. Antibacterial activity of each compound was evaluated by measuring the zone of growth inhibition against the test organisms with zone reader (Hi Antibiotic zone scale). DMSO was used as a negative control whereas ciprofloxacin was used as a positive control. This procedure was performed in three replicate plates for each organism [22, 23].

Determination of minimum inhibitory concentration

Minimum inhibitory concentration (MIC) is the lowest concentration of an antimicrobial compound that will inhibit the visible growth of a microorganism after overnight incubation. MIC of the compounds against bacterial strains was tested through a macrodilution tube method as recommended by NCCLS [24]. In this method, various test concentrations of chemically synthesized compounds were made from 256 to 1 μg/mL in sterile tubes, 1-10. 100 μL sterile Mueller Hinton Broth was poured in each sterile tube, and followed by addition of 200 μL test compound in tube 1. Twofold serial dilutions were carried out from tubes 1 to 10, and excess broth (100 μL) was discarded from the tube 10. To each tube, 100 μL of standard inoculum (1.5 × 108 cfu/mL) was added. Ciprofloxacin was used as control. Turbidity was observed after incubating the inoculated tubes at 37°C for 24 h.

In vitro antifungal activity

The antifungal activity of the synthesized chemical compounds was evaluated by poison food technique. The moulds were grown on SDA at 25°C for 7 days and used as inocula. 15 mL of molten SDA (45°C) was poisoned by the addition of 100 μL volume of each compound having concentration of 4.0 mg/mL, reconstituted in the DMSO, poured into a sterile Petri plate and allowed to solidify at room temperature. The solidified poisoned agar plates were inoculated at the centre with fungal plugs (8-mm diameter), obtained from the actively growing colony and incubated at 25°C for 7 days. DMSO was used as the negative control whereas fluconazole was used as the positive control. The experiments were performed in triplicates. Diameter of the fungal colonies was measured and expressed as percent mycelial inhibition determined by applying the following formula [25]:
https://static-content.springer.com/image/art%3A10.1186%2F2191-2858-1-5/MediaObjects/13588_2011_Article_4_Equa_HTML.gif

where dc is the average diameter of fungal colony in negative control plates, and dt the average diameter of fungal colony in experimental plates.

Abbreviations

1: 

4-DHP: dialkyl 1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylates

DMSO: 

dimethylsulphoxide

HTIB: 

hydroxy (tosyloxy)iodobenzene

MIC: 

minimum inhibitory concentration

MTCC: 

microbial type culture collection

SDA: 

Sabouraud dextrose agar.

Declarations

Acknowledgements

We are thankful to the CSIR, New Delhi (Grant no. CSIR 01 (2816)/07/EMR-II) for providing financial assistance to accomplish this research. The authors are also grateful to the CSIR for the award of junior research fellowship to Khalid Hussain.

Authors’ Affiliations

(1)
Institute of Pharmaceutical Sciences, Kurukshetra University
(2)
Department of Chemistry, Guru Nanak Khalsa College
(3)
Department of Chemistry, Dyal Singh College
(4)
Department of Chemistry, Kurukshetra University
(5)
Department of Microbiology, Kurukshetra University

References

  1. Loev B, Goodman M, Snader K, Tedeschi R, Macko E: Hantzsch-type dihydropyridine hypotensive agents. J Med Chem 1974, 17: 956. 10.1021/jm00255a010View ArticleGoogle Scholar
  2. Katzung BG: Basic and clinical pharmacology. Appleton & Lange, Stamford; 1998.Google Scholar
  3. Bossert F, Meyer H, Wehinger E: 4-Aryldihydropyridines, a new class of highly active calcium antagonists. Angew Chem Int Ed Engl 1981, 20: 762. 10.1002/anie.198107621View ArticleGoogle Scholar
  4. Klusa V: Cerebrocrast neuroprotectant cognition enhancer. Drugs Fut 1995, 20: 135.View ArticleGoogle Scholar
  5. Godfraind T, Miller R, Wibo M: Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986, 38: 321.Google Scholar
  6. Sausins A, Duburs G: Synthesis of 1,4-dihydropyridines by cyclocondensation reactions. Heterocycles 1988, 27: 269. 10.3987/REV-87-370View ArticleGoogle Scholar
  7. Gaudio AC, Korolkovas A, Takahata Y: Quantitative structure-activity relationships for 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues): A quantum chemical/classical approach. J Pharm Sci 1994, 83: 1110. 10.1002/jps.2600830809View ArticleGoogle Scholar
  8. Cooper K, Fray M J, Parry M J, Richardson K, Steele J: 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives. J Med Chem 1992, 35: 3115. 10.1021/jm00095a005View ArticleGoogle Scholar
  9. Yadav JS, Reddy VS, Reddy PT: Unprecedented synthesis of hantzsch 1,4-dihydropyridines under biginelli reaction conditions. Synth Commun 2001, 31: 425. 10.1081/SCC-100000534View ArticleGoogle Scholar
  10. Kumar R, Malik S, Chandra R: Synthesis and antimicrobial evaluation of 4-(5-chloro-3-methyl-1-phenyl-1 H-pyrazol-4-yl)-dihydropyridines and 4-(5-chloro-3-methyl-1-phenyl-1 H-pyrazol-4-yl)-3,4-dihydropyrimidin-2-ones. Ind J Chem 2009, 48B: 718–724.Google Scholar
  11. Böcker RH, Guengerich FP: Oxidation of 4-aryl- and 4-alkyl-substituted 2,6-dimethyl-3,5-bis(alkoxycarbonyl)-1,4-dihydropyridines by human liver microsomes and immunochemical evidence for the involvement of a form of cytochrome P-450. J Med Chem 1986, 29: 1596–1603. 10.1021/jm00159a007View ArticleGoogle Scholar
  12. Prakash O, Singh SP: Iodobenzene diacetate and related hypervalent iodine (III) reagents in the synthesis of heterocyclic compounds. Aldrichimica Acta 1994, 27: 15–22.Google Scholar
  13. Prakash O, Sharma D, Kamal R, Kumar R, Nair RR: The chemistry of α, β-chalcone ditosyloxy ketones: new and convenient route for the synthesis of 1,4,5-trisubstituted pyrazoles from α, β-chalcone ditosylates. Tetrahedron 2009,68(49):10175–10181.View ArticleGoogle Scholar
  14. Prakash O, Kumar M, Kumar R: A novel and convenient approach for tosyloxylation of aromatic ring of some ortho-substituted phenolic compounds using [hydroxy(tosyloxy)iodo]benzene. Tetrahedron 2010,66(31):5827–5832. 10.1016/j.tet.2010.05.042View ArticleGoogle Scholar
  15. Varvoglis A: Chemical transformations induced by hypervalent iodine reagents. Tetrahedron 1997, 53: 1179. 10.1016/S0040-4020(96)00970-2View ArticleGoogle Scholar
  16. Ladziata U, Zhdankin VV: Hypervalent (V) reagents in organic synthesis. Arkivoc 2006, ix: 26–58.View ArticleGoogle Scholar
  17. Zhdankin VV: Hypervalent (III) reagents in organic synthesis. Arkivoc 2009, i: 1–62.View ArticleGoogle Scholar
  18. Lee K-H, Ko K-Y: Aromatization of Hantzsch 1,4-dihydropyridines using [Hydroxy(tosyloxy)iodo]benzene. Bull Korean Chem Soc 2002,23(11):1505–1506.View ArticleGoogle Scholar
  19. Kira MA, Abdel-Rahman MO, Gadalla KZ: Vilsmeier reaction-III cyclization of hydrazones to pyrazoles. Tetrahedron Lett 1969, 10: 109–110. 10.1016/S0040-4039(01)88217-4View ArticleGoogle Scholar
  20. Murugan R, Ramamoorthy K, Sundarrajan S, Ramakrishna S: Simple and efficient synthesis of 2,6-dialkyl-3,5-dialkoxycarbonyl-4-(3-aryl-1-phenyl-pyrazol-4-yl) using TPAP/NMO as a catalyst under mild conditions. Tetrahedron 2011.Google Scholar
  21. Aneja KR, Sharma C, Joshi R: Fungal infection of the ear: a common problem in the north eastern part of Haryana. Int J Pediatr Otorhinolaryngol 2010, 74: 604–607. 10.1016/j.ijporl.2010.03.001View ArticleGoogle Scholar
  22. Ahmad I, Beg AJ: Antimicrobial and phytochemical studies on 45 Indian medicinal plants against multi-drug resistant human pathogens. J Ethnopharmacol 2001, 74: 113–123. 10.1016/S0378-8741(00)00335-4View ArticleGoogle Scholar
  23. Andrews JM: Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001, 48: 5–16.View ArticleGoogle Scholar
  24. NCCLS: Method for dilution antimicrobial susceptibility test for bacteria that grow aerobically approved standards. 5th edition. National Committee for Clinical Standards, Villanova, PA; 2000.Google Scholar
  25. Al-Burtamani SKS, Fatope MO, Marwah RG, Onifade AK, Al-Saidi SH: Chemical composition, antibacterial and antifungal activities of the essential oil of Haplophyllum tuberculatum . J Ethnopharmocol 2005, 96: 107–112. 10.1016/j.jep.2004.08.039View ArticleGoogle Scholar

Copyright

© Prakash et al; licensee Springer. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.